Mutual of America Capital Management LLC grew its position in Zoetis Inc. (NYSE:ZTS) by 0.4% in the third quarter, HoldingsChannel reports. The fund owned 62,282 shares of the company’s stock after acquiring an additional 239 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Zoetis were worth $12,091,000 at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. Financial Management Professionals Inc. purchased a new stake in shares of Zoetis during the third quarter worth about $25,000. West Oak Capital LLC purchased a new stake in shares of Zoetis during the third quarter worth about $29,000. JJJ Advisors Inc. grew its stake in Zoetis by 216.7% during the 3rd quarter. JJJ Advisors Inc. now owns 152 shares of the company’s stock valued at $30,000 after acquiring an additional 104 shares in the last quarter. Ogorek Anthony Joseph NY ADV purchased a new stake in Zoetis during the 3rd quarter valued at about $29,000. Finally, McClarren Financial Advisors Inc. grew its stake in Zoetis by 45.1% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 209 shares of the company’s stock valued at $40,000 after acquiring an additional 65 shares in the last quarter. Institutional investors and hedge funds own 89.65% of the company’s stock.
In other news, EVP Roxanne Lagano sold 1,315 shares of the company’s stock in a transaction dated Thursday, December 23rd. The shares were sold at an average price of $241.70, for a total transaction of $317,835.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kristin C. Peck sold 14,500 shares of the stock in a transaction dated Friday, November 26th. The shares were sold at an average price of $223.10, for a total transaction of $3,234,950.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 41,837 shares of company stock valued at $9,155,881. 0.17% of the stock is owned by insiders.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, November 4th. The company reported $1.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.15. The firm had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $1.93 billion. Zoetis had a net margin of 26.02% and a return on equity of 52.17%. Zoetis’s revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.10 earnings per share. As a group, analysts forecast that Zoetis Inc. will post 4.66 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 1st. Shareholders of record on Thursday, January 20th will be paid a dividend of $0.325 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.25. The ex-dividend date is Wednesday, January 19th. This represents a $1.30 annualized dividend and a yield of 0.63%. Zoetis’s payout ratio is presently 24.10%.
ZTS has been the subject of several research reports. Citigroup upped their price objective on shares of Zoetis from $184.00 to $232.00 and gave the company a “neutral” rating in a research note on Monday, December 20th. Barclays upped their price objective on shares of Zoetis from $235.00 to $240.00 and gave the company an “overweight” rating in a research note on Friday, November 5th. They noted that the move was a valuation call. Zacks Investment Research cut shares of Zoetis from a “buy” rating to a “hold” rating and set a $242.00 price target for the company. in a research note on Saturday, January 8th. Finally, Morgan Stanley began coverage on shares of Zoetis in a research note on Thursday, November 18th. They issued an “overweight” rating and a $264.00 price target for the company. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $222.70.
Zoetis, Inc discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.
Recommended Story: What are retained earnings?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.